US-based digital therapeutics developer Click Therapeutics has secured $19m in a funding round led by Sanofi Ventures, the corporate venturing arm of pharmaceutical firm Sanofi.
Another drug producer, Hikma Pharmaceuticals, also took part in the round, investing through its Hikma International Ventures and Development subsidiary. Its previous close was reached in July this year.
Founded in 2012, Click Therapeutics creates mobile apps that help patients manage health issues including cognitive or neurobehavioural disorders through features such as a habit diary, breathing exercises and the option of contacting a medical professional.
The company has already launched a smoking cessation app in the US and is conducting late-stage clinical trials on products for major depressive disorder and insomnia. Other treatments in its pipeline include apps concentrating on chronic pain and acute coronary syndrome.
The latest round comes after Click raised $7.4m in debt financing between 2014 and April 2017, according to regulatory filings.
Supernode Ventures backed a seed round of undisclosed size for Click in 2015, and the company has a development partnership in place with healthcare provider Magellan Health, which took a board seat in 2016 but has not publicly disclosed an equity investment.